Diabetic nephropathy (DN) is the leading cause of end-stage renal disease globally. Currently, there are no effective drugs for the treatment of DN. Although several studies have reported the therapeutic potential of mesenchymal stem cells, the underlying mechanisms remain largely unknown. Here, we report that both human umbilical cord MSCs (UC-MSCs) and UC-MSC-derived exosomes (UC-MSC-exo) attenuate kidney damage, and inhibit epithelial-mesenchymal transition (EMT) and renal fibrosis in streptozotocin-induced DN rats. Strikingly, the Hedgehog receptor, smoothened (SMO), was significantly upregulated in the kidney tissues of DN patients and rats, and positively correlated with EMT and renal fibrosis. UC-MSC and UC-MSC-exo treatment resulted in decrease of SMO expression. In vitro co-culture experiments revealed that UC-MSC-exo reduced EMT of tubular epithelial cells through inhibiting Hedgehog/SMO pathway. Collectively, UC-MSCs inhibit EMT and renal fibrosis by delivering exosomes and targeting Hedgehog/SMO signaling, suggesting that UC-MSCs and their exosomes are novel anti-fibrotic therapeutics for treating DN.

Open Research

DATA AVAILABILITY STATEMENT

All data generated and/or analyzed during this study are included in this published article.

Supporting Information

REFERENCES

1Johansen KL, Chertow GM, Foley RN, et al. US renal data system 2020 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2021; 77(4 Suppl 1): A7-A8. doi:10.1053/j.ajkd.2021.01.002
10.1053/j.ajkd.2021.01.002
PubMedWeb of Science®Google Scholar
2de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011; 305(24): 2532-2539. doi:10.1001/jama.2011.861
10.1001/jama.2011.861
PubMedWeb of Science®Google Scholar
3Srivastava SP, Li J, Kitada M, et al. SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis. Cell Death Dis. 2018; 9(10): 997. doi:10.1038/s41419-018-1057-0
10.1038/s41419-018-1057-0
PubMedGoogle Scholar
4Declèves A-E, Sharma K. New pharmacological treatments for improving renal outcomes in diabetes. Nat Rev Nephrol. 2010; 6(6): 371-380. doi:10.1038/nrneph.2010.57
10.1038/nrneph.2010.57
CASPubMedWeb of Science®Google Scholar
5Kheirollahi V, Wasnick RM, Biasin V, et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat Commun. 2019; 10(1): 2987. doi:10.1038/s41467-019-10839-0
10.1038/s41467-019-10839-0
PubMedWeb of Science®Google Scholar
6Srivastava SP, Zhou H, Setia O, et al. Loss of endothelial glucocorticoid receptor accelerates diabetic nephropathy. Nat Commun. 2021; 12(1): 2368. doi:10.1038/s41467-021-22617-y
10.1038/s41467-021-22617-y
CASPubMedWeb of Science®Google Scholar
7Simonson MS. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int. 2007; 71(9): 846-854.
10.1038/sj.ki.5002180
CASPubMedWeb of Science®Google Scholar
8Nieto MA, Huang RY-J, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016; 166(1): 21-45. doi:10.1016/j.cell.2016.06.028
10.1016/j.cell.2016.06.028
CASPubMedWeb of Science®Google Scholar
9Shu DY, Lovicu FJ. Myofibroblast transdifferentiation: the dark force in ocular wound healing and fibrosis. Prog Retin Eye Res. 2017; 60: 44-65. doi:10.1016/j.preteyeres.2017.08.001
10.1016/j.preteyeres.2017.08.001
PubMedWeb of Science®Google Scholar
10Gonzalez DM, Medici D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci Signal. 2014; 7(344):re8. doi:10.1126/scisignal.2005189
10.1126/scisignal.2005189
PubMedWeb of Science®Google Scholar
11Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int. 2006; 69(2): 213-217.
10.1038/sj.ki.5000054
CASPubMedWeb of Science®Google Scholar
12Liu Z, Xu J, He J, et al. A critical role of autocrine sonic hedgehog signaling in human CD138⁺ myeloma cell survival and drug resistance. Blood. 2014; 124(13): 2061-2071. doi:10.1182/blood-2014-03-557298
10.1182/blood-2014-03-557298
CASPubMedWeb of Science®Google Scholar
13Yang C, Chen W, Chen Y, Jiang J. Smoothened transduces hedgehog signal by forming a complex with Evc/Evc2. Cell Res. 2012; 22(11): 1593-1604. doi:10.1038/cr.2012.134
10.1038/cr.2012.134
CASPubMedWeb of Science®Google Scholar
14Chung CH, Dignam JJ, Hammond ME, et al. Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). J Clin Oncol. 2011; 29(10): 1326-1334. doi:10.1200/JCO.2010.32.3295
10.1200/JCO.2010.32.3295
PubMedWeb of Science®Google Scholar
15Qu C, Liu Y, Kunkalla K, et al. Trimeric G protein-CARMA1 axis links smoothened, the hedgehog receptor transducer, to NF-κB activation in diffuse large B-cell lymphoma. Blood. 2013; 121(23): 4718-4728. doi:10.1182/blood-2012-12-470153
10.1182/blood-2012-12-470153
CASPubMedWeb of Science®Google Scholar
16Chaudhry P, Singh M, Triche TJ, Guzman M, Merchant AA. GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML. Blood. 2017; 129(26): 3465-3475. doi:10.1182/blood-2016-05-718585
10.1182/blood-2016-05-718585
CASPubMedWeb of Science®Google Scholar
17Edeling M, Ragi G, Huang S, Pavenstädt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016; 12(7): 426-439. doi:10.1038/nrneph.2016.54
10.1038/nrneph.2016.54
CASPubMedWeb of Science®Google Scholar
18Charbord P. Bone marrow mesenchymal stem cells: historical overview and concepts. Hum Gene Ther. 2010; 21(9): 1045-1056. doi:10.1089/hum.2010.115
10.1089/hum.2010.115
CASPubMedWeb of Science®Google Scholar
19Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment of exosome composition. Cell. 2019; 177(2): 428-445.e18. doi:10.1016/j.cell.2019.02.029
10.1016/j.cell.2019.02.029
CASPubMedWeb of Science®Google Scholar
20Pegtel DM, Gould SJ. Exosomes. Annu Rev Biochem. 2019; 88: 487-514. doi:10.1146/annurev-biochem-013118-111902
10.1146/annurev-biochem-013118-111902
CASPubMedWeb of Science®Google Scholar
21Xiang E, Han B, Zhang Q, et al. Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020; 11(1): 336. doi:10.1186/s13287-020-01852-y
10.1186/s13287-020-01852-y
CASPubMedWeb of Science®Google Scholar
22Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016; 12(1): 13-26. doi:10.1038/nrneph.2015.175
10.1038/nrneph.2015.175
CASPubMedWeb of Science®Google Scholar
23Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, García-Pérez J. Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy. Nat Rev Nephrol. 2011; 7(6): 327-340. doi:10.1038/nrneph.2011.51
10.1038/nrneph.2011.51
CASPubMedWeb of Science®Google Scholar
24Omenetti A, Porrello A, Jung Y, et al. Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. J Clin Invest. 2008; 118(10): 3331-3342. doi:10.1172/JCI35875
10.1172/JCI35875
CASPubMedWeb of Science®Google Scholar
25Magee C, Grieve DJ, Watson CJ, Brazil DP. Diabetic nephropathy: a tangled web to unweave. Cardiovasc Drugs Ther. 2017; 31(5–6): 579-592. doi:10.1007/s10557-017-6755-9
10.1007/s10557-017-6755-9
PubMedWeb of Science®Google Scholar
26Sun H, Saeedi P, Karuranga S, et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183:109119. doi:10.1016/j.diabres.2021.109119
10.1016/j.diabres.2021.109119
PubMedWeb of Science®Google Scholar
27Dagar N, Das P, Bisht P, Taraphdar AK, Velayutham R, Arumugam S. Diabetic nephropathy: a twisted thread to unravel. Life Sci. 2021; 278:119635. doi:10.1016/j.lfs.2021.119635
10.1016/j.lfs.2021.119635
CASPubMedWeb of Science®Google Scholar
28Ricciardi CA, Gnudi L. Kidney disease in diabetes: from mechanisms to clinical presentation and treatment strategies. Metabolism. 2021; 124:154890. doi:10.1016/j.metabol.2021.154890
10.1016/j.metabol.2021.154890
CASPubMedWeb of Science®Google Scholar
29Leiker M, Suzuki G, Iyer VS, Canty JM, Lee T. Assessment of a nuclear affinity labeling method for tracking implanted mesenchymal stem cells. Cell Transplant. 2008; 17(8): 911-922.
10.3727/096368908786576444
PubMedWeb of Science®Google Scholar
30Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine mechanisms in adult stem cell signaling and therapy. Circ Res. 2008; 103(11): 1204-1219. doi:10.1161/CIRCRESAHA.108.176826
10.1161/CIRCRESAHA.108.176826
CASPubMedWeb of Science®Google Scholar
31Camussi G, Deregibus MC, Cantaluppi V. Role of stem-cell-derived microvesicles in the paracrine action of stem cells. Biochem Soc Trans. 2013; 41(1): 283-287. doi:10.1042/BST20120192
10.1042/BST20120192
CASPubMedWeb of Science®Google Scholar
32Duan Y-R, Chen B-P, Chen F, et al. Exosomal microRNA-16-5p from human urine-derived stem cells ameliorates diabetic nephropathy through protection of podocyte. J Cell Mol Med. 2021; 25(23): 10798-10813. doi:10.1111/jcmm.14558
10.1111/jcmm.14558
CASPubMedGoogle Scholar
33Jin J, Shi Y, Gong J, et al. Exosome secreted from adipose-derived stem cells attenuates diabetic nephropathy by promoting autophagy flux and inhibiting apoptosis in podocyte. Stem Cell Res Ther. 2019; 10(1): 95. doi:10.1186/s13287-019-1177-1
10.1186/s13287-019-1177-1
CASPubMedWeb of Science®Google Scholar
34Ezquer F, Ezquer M, Simon V, et al. Endovenous administration of bone-marrow-derived multipotent mesenchymal stromal cells prevents renal failure in diabetic mice. Biol Blood Marrow Transplant. 2009; 15(11): 1354-1365. doi:10.1016/j.bbmt.2009.07.022
10.1016/j.bbmt.2009.07.022
CASPubMedWeb of Science®Google Scholar
35Li Y, Liu J, Liao G, et al. Early intervention with mesenchymal stem cells prevents nephropathy in diabetic rats by ameliorating the inflammatory microenvironment. Int J Mol Med. 2018; 41(5): 2629-2639. doi:10.3892/ijmm.2018.3501
10.3892/ijmm.2018.3501
CASPubMedWeb of Science®Google Scholar
36Bai Y, Wang J, He Z, Yang M, Li L, Jiang H. Mesenchymal stem cells reverse diabetic nephropathy disease via lipoxin A4 by targeting transforming growth factor β (TGF-β)/smad pathway and pro-inflammatory cytokines. Med Sci Monit. 2019; 25: 3069-3076. doi:10.12659/MSM.914860
10.12659/MSM.914860
CASPubMedWeb of Science®Google Scholar
37Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nat Rev Nephrol. 2018; 14(8): 493-507. doi:10.1038/s41581-018-0023-5
10.1038/s41581-018-0023-5
CASPubMedWeb of Science®Google Scholar
38Harrell CR, Fellabaum C, Jovicic N, Djonov V, Arsenijevic N, Volarevic V. Molecular mechanisms responsible for therapeutic potential of mesenchymal stem cell-derived secretome. Cells. 2019; 8(5):467. doi:10.3390/cells8050467
10.3390/cells8050467
CASPubMedWeb of Science®Google Scholar
39Zou X, Zhang G, Cheng Z, et al. Microvesicles derived from human Wharton's Jelly mesenchymal stromal cells ameliorate renal ischemia-reperfusion injury in rats by suppressing CX3CL1. Stem Cell Res Ther. 2014; 5(2): 40. doi:10.1186/scrt428
10.1186/scrt428
PubMedWeb of Science®Google Scholar
40Zhang Y, Le X, Zheng S, et al. MicroRNA-146a-5p-modified human umbilical cord mesenchymal stem cells enhance protection against diabetic nephropathy in rats through facilitating M2 macrophage polarization. Stem Cell Res Ther. 2022; 13(1): 171. doi:10.1186/s13287-022-02855-7
10.1186/s13287-022-02855-7
CASPubMedWeb of Science®Google Scholar
41Song N, Zhang T, Xu X, et al. miR-21 protects against ischemia/reperfusion-induced acute kidney injury by preventing epithelial cell apoptosis and inhibiting dendritic cell maturation. Front Physiol. 2018; 9:790. doi:10.3389/fphys.2018.00790
10.3389/fphys.2018.00790
PubMedWeb of Science®Google Scholar
42Li JH, Zhu H-J, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-Beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol. 2002; 13(6): 1464-1472.
10.1097/01.ASN.0000014252.37680.E4
CASPubMedWeb of Science®Google Scholar
43Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19(2): 156-172. doi:10.1038/cr.2009.5
10.1038/cr.2009.5
CASPubMedWeb of Science®Google Scholar
44Falke LL, Gholizadeh S, Goldschmeding R, Kok RJ, Nguyen TQ. Diverse origins of the myofibroblast—implications for kidney fibrosis. Nat Rev Nephrol. 2015; 11(4): 233-244. doi:10.1038/nrneph.2014.246
10.1038/nrneph.2014.246
CASPubMedWeb of Science®Google Scholar
45Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011; 7(12): 684-696. doi:10.1038/nrneph.2011.149
10.1038/nrneph.2011.149
CASPubMedWeb of Science®Google Scholar
46Grande MT, Sánchez-Laorden B, López-Blau C, et al. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 2015; 21(9): 989-997. doi:10.1038/nm.3901
10.1038/nm.3901
CASPubMedWeb of Science®Google Scholar
47LeBleu VS, Taduri G, O'Connell J, et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med. 2013; 19(8): 1047-1053. doi:10.1038/nm.3218
10.1038/nm.3218
CASPubMedWeb of Science®Google Scholar
48Humphreys BD, Lin S-L, Kobayashi A, et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol. 2010; 176(1): 85-97. doi:10.2353/ajpath.2010.090517
10.2353/ajpath.2010.090517
CASPubMedWeb of Science®Google Scholar
49Elovikova AN, Gvozdeva LM, Buberman KL, Sorokina VP, Korol'kova EN. Orthodontic treatment results with dental arch anomalies in children and adolescents with and without removal of the teeth. Stomatologiia (Mosk). 1989; 68(6): 60-62.
CASPubMedGoogle Scholar
50Lovisa S, LeBleu VS, Tampe B, et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat Med. 2015; 21(9): 998-1009. doi:10.1038/nm.3902
10.1038/nm.3902
CASPubMedWeb of Science®Google Scholar
51Bufalieri F, Infante P, Bernardi F, et al. ERAP1 promotes Hedgehog-dependent tumorigenesis by controlling USP47-mediated degradation of βTrCP. Nat Commun. 2019; 10(1): 3304. doi:10.1038/s41467-019-11093-0
10.1038/s41467-019-11093-0
PubMedGoogle Scholar
52Ng JMY, Curran T. The Hedgehog's tale: developing strategies for targeting cancer. Nat Rev Cancer. 2011; 11(7): 493-501. doi:10.1038/nrc3079
10.1038/nrc3079
CASPubMedWeb of Science®Google Scholar
53Shen X, Peng Y, Li H. The injury-related activation of hedgehog signaling pathway modulates the repair-associated inflammation in liver fibrosis. Front Immunol. 2017; 8:1450. doi:10.3389/fimmu.2017.01450
10.3389/fimmu.2017.01450
PubMedWeb of Science®Google Scholar
54Takebe N, Warren RQ, Ivy SP. Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res. 2011; 13(3): 211. doi:10.1186/bcr2876
10.1186/bcr2876
PubMedWeb of Science®Google Scholar
55Li Y, Hu Q, Li C, et al. PTEN-induced partial epithelial-mesenchymal transition drives diabetic kidney disease. J Clin Invest. 2019; 129(3): 1129-1151. doi:10.1172/JCI121987
10.1172/JCI121987
PubMedWeb of Science®Google Scholar
56Li Y, Sun X, Gao D, et al. Dual functions of Rack1 in regulating hedgehog pathway. Cell Death Differ. 2020; 27(11): 3082-3096. doi:10.1038/s41418-020-0563-7
10.1038/s41418-020-0563-7
CASPubMedWeb of Science®Google Scholar
57Zhang P, Gao H, Yan R, Yu L, Xia C, Yang D. has_circ_0070512 promotes prostate cancer progression by regulating the miR-338-3p/hedgehog signaling pathway. Cancer Sci. 2023; 114(4): 1491-1506. doi:10.1111/cas.15672
10.1111/cas.15672
CASPubMedWeb of Science®Google Scholar
58Gao Q, Chang X, Yang M, et al. LncRNA MEG3 restrained pulmonary fibrosis induced by NiO NPs via regulating hedgehog signaling pathway-mediated autophagy. Environ Toxicol. 2022; 37(1): 79-91. doi:10.1002/tox.23379
10.1002/tox.23379
CASPubMedWeb of Science®Google Scholar
59Li L, Zhang L, Zhao X, Cao J, Li J, Chu G. Downregulation of miR-152 contributes to the progression of liver fibrosis via targeting Gli3 in vivo and in vitro. Exp Ther Med. 2019; 18(1): 425-434. doi:10.3892/etm.2019.7595
10.3892/etm.2019.7595
CASPubMedWeb of Science®Google Scholar
60Kim J, Lee C, Shin Y, et al. sEVs from tonsil-derived mesenchymal stromal cells alleviate activation of hepatic stellate cells and liver fibrosis through miR-486-5p. Mol Ther. 2021; 29(4): 1471-1486. doi:10.1016/j.ymthe.2020.12.025
10.1016/j.ymthe.2020.12.025
CASPubMedWeb of Science®Google Scholar
61Xiao K, He W, Guan W, et al. Mesenchymal stem cells reverse EMT process through blocking the activation of NF-κB and hedgehog pathways in LPS-induced acute lung injury. Cell Death Dis. 2020; 11(10): 863. doi:10.1038/s41419-020-03034-3
10.1038/s41419-020-03034-3
CASPubMedWeb of Science®Google Scholar

Volume38, Issue7

15 April 2024

e23599

Filename	Description
fsb223599-sup-0001-FiguresS1-S5.pdfPDF document, 2.4 MB	Figures S1-S5.
fsb223599-sup-0002-TableS1.docxWord 2007 document , 12.8 KB	Table S1.

Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate renal fibrosis in diabetic nephropathy by targeting Hedgehog/SMO signaling

Abstract

Open Research

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate renal fibrosis in diabetic nephropathy by targeting Hedgehog/SMO signaling

Abstract

Open Research

DATA AVAILABILITY STATEMENT

Supporting Information

REFERENCES

References

Related

Information